{
  "id": 5442898,
  "title": "Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)",
  "url": "https://urgent.news/2026/09/03/stoke-therapeutics-and-biogen-present-long-term-clinical-data-that",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-03T23:34:49.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/stoke-therapeutics-and-biogen-present-long-term-clinical-data-that-support-the-disease-modifying-potential-of-zorevunersen-an-investigational-medicine-for-the-treatment-of-dravet-syndrome-at-the-16t"
  },
  "original_language": "en",
  "account": null,
  "summary": "–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines– –New data showed substantial reductions in the most severe seizure types, the leading risk factor for sudden unexpected […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}